# US 2006/0217788 A1 · Method of using laser induced injury to activate topical prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0217788 A1
- Document ID: US20060217788A1
- Status: Published application
- Kind: A1
- Application number: 11/318,372
- Filed: 2005-12-22
- Published: 2006-09-28
- Earliest claimed: 2004-07-09
- Inventors: G. Herron; D. Bommannan
- Web page: https://patentgrep.com/patent/US20060217788A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions are disclosed for improving the wound healing process and increasing collagen synthesis following laser induced thermal injury. The method comprises delivering prodrugs to a target site before the target site is injured and taking advantage of those enzymes that are physiologically-expressed to promote wound healing to convert the prodrugs to active drugs. The claimed invention has the advantage of the prodrugs being readily available to immediately participate in the wound healing process, but not have any negative side-effects of the active drug being present before injury occurs.

## Claims

### Claim 1

A method of activating a prodrug comprising:
administering the prodrug to a target tissue, wherein the prodrug has a moiety that is cleavable by an activator wherein the activator is secreted because of injury to the target tissue; and
the activator converts the prodrug into active drug.

### Claim 2 (depends on 1)

The method of claim 1, where the target tissue is skin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the injury is due to laser exposure to the skin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the activator is an enzyme.

### Claim 5 (depends on 4)

The method of claim 4, wherein the enzyme is selected from the group consisting of a protease (including metalloproteinase, serine protease and thiol proteinases), a glycosidase, a kinase, a phosphodiesterase, a phosphorylase, a sulfatase, an esterase, a lipase, an oxygenase, a dismutase, a hydroxylase, a ligase and a synthase, or combinations thereof.

### Claim 6

A prodrug to treat a target tissue, wherein the prodrug comprises the formula
S-A
wherein S is a substrate cleavable by catalytic agent where the substrate is cleaved only in the presence of the catalytic agent that is not present in healthy target tissue but only secreted upon injury to the target tissue; and
A is a drug.

### Claim 7 (depends on 6)

The prodrug of claim 6, where the target tissue is skin.

### Claim 8 (depends on 7)

The prodrug of claim 7, where the drug is selected from the list consisting of tetracycline, doxycycline, halofuginone, Periostat, Trocade, FR255031, doxorubicin, N-acetylcysteine, minocycline, and colchicine, or combinations thereof.

### Claim 9 (depends on 8)

The prodrug of claim 8, where the injury is laser exposure to the skin.

### Claim 10 (depends on 9)

The prodrug of claim 9, wherein the catalytic agent is an enzyme selected from the group consisting of a protease, glycosidase, a kinase, a phosphodiesterase, a phosphorylase, a sulfatase, an esterase, a lipase, an oxygenase, a dismutase, a hydroxylase, a ligase and a synthase, or combinations thereof.

### Claim 11 (depends on 10)

The prodrug of claim 10, wherein the enzyme is a protease selected from the group consisting of metalloproteinase, serine protease and thiol proteinase.

### Claim 12 (depends on 11)

The prodrug of claim 11, wherein the enzyme is a metalloproteinase.

### Claim 13 (depends on 12)

The prodrug of claim 12, wherein the metalloproteinase is collagenase.

### Claim 14 (depends on 1)

The prodrug of claim 1, wherein S is PLGLAARK (SEQ ID NO: 2).

### Claim 15 (depends on 14)

The prodrug of claim 14, wherein A is a pentapeptide or a tripeptide.

### Claim 16 (depends on 15)

The prodrug of claim 15, wherein A is KTTKS (SEQ ID NO: 1), GHK, GHK-Cu, analogs, derivatives or combinations thereof.

### Claim 17 (depends on 14)

The prodrug of claim 14, wherein A further comprises an acyl group.

### Claim 18 (depends on 17)

The prodrug of claim 17, wherein the acyl group is palmitoyl group, elaidoyl group, or myrityl group.

### Claim 19

A method of improving healing of skin wounds, the method comprising:
administering a prodrug to the skin wherein the prodrug comprises the formula S-A, wherein S is cleavable by a catalytic agent and A is a drug, and wherein the active agent is present in wounds.

### Claim 20 (depends on 19)

The method of claim 19, wherein the S is a carboxylate, an ester, and amide, or an aldehyde.

### Claim 21 (depends on 20)

The method of claim 20, wherein S is a carboxylate.

### Claim 22 (depends on 19)

The method of claim 19, wherein A is selected from the list consisting of tetracycline, doxycycline, halofuginone, Periostat, Trocade, FR255031, doxorubicin, N-acetylcysteine, minocycline, and colchicine, or combinations thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein A is tetracycline.

### Claim 24 (depends on 22)

The method of claim 22, wherein A is doxycycline.

### Claim 25 (depends on 22)

The method of claim 22, wherein A is doxorubicin.

### Claim 26 (depends on 19)

The method of claim 19, wherein the active agent is an enzyme selected from the group consisting of a protease, glycosidase, a kinase, a phosphodiesterase, a phosphorylase, a sulfatase, an esterase, a lipase, an oxygenase, a dismutase, a hydroxylase, a ligase and a synthase, or combinations thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the enzyme is a protease selected from the group consisting of metalloproteinase, serine protease and thiol proteinase.

### Claim 28 (depends on 27)

The method of claim 27, wherein the enzyme is a metalloproteinase.

### Claim 29 (depends on 28)

The method of claim 28, wherein the metalloproteinase is collagenase.

### Claim 30 (depends on 19)

The method of claim 19, where the skin wound is due to laser exposure.

### Claim 31 (depends on 19)

The method of claim 19, wherein A is a growth factors selected from the group consisting of EGF, bFGF, aFGF, TGF-α, TGF-β, KGF, NGF, PDGF, insulin, insulin-like Growth Factors I and II (IGF-I and IGF-II, respectively), interferons (IFNs), Interleukins (ILs), KGF (Keratinocyte Growth Factor), Macrophage Colony Stimulating Factor (M-CSF), Platelet-Derived Endothelial Cell Growth Factor (PD-ECGF), Stem Cell Factor (SCF), and tumor necrosis factor alpha (TNF-α), or combinations thereof.

### Claim 32 (depends on 19)

The method of claim 19, wherein S is PLGLAARK (SEQ ID NO: 2).

### Claim 33 (depends on 32)

The method of claim 32, wherein A is a pentapeptide or a tripeptide.

### Claim 34 (depends on 33)

The method of claim 33, wherein A is KTTKS (SEQ ID NO: 1), GHK, GHK-Cu, analogs, derivatives or combinations thereof.

### Claim 35 (depends on 32)

The method of claim 32, wherein A further comprises an acyl group.

### Claim 36 (depends on 35)

The method of claim 35, wherein the acyl group is palmitoyl group, elaidoyl group, or myrityl group.
